Floatz logo

Kite-753

B-Cell Acute Lymphoblastic Leukemia

M.D. Anderson Cancer CenterCell therapyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

140 Active assets in the B-Cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Kite-753 is also rated in:

relapsed/refractory diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
cancerDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →